LEADing Dementia End-of-Life Planning Conversations

Sponsor
University of Utah (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05909189
Collaborator
National Institute on Aging (NIA) (NIH)
120
1
40.9

Study Details

Study Description

Brief Summary

Advance care planning is important for all adults, but perhaps even more so for the 5.7 million persons with Alzheimer's disease or related dementia (ADRD), due to the progressive and protracted cognitive deterioration associated with the disease process. In the context of ADRD, medical decision-making at the end of life is typically left to one's care partner, who often does not have the knowledge or confidence in their ability to make such decisions. This study will refine and evaluate a web-based platform, called the LEAD Intervention (Life-Planning in Early Alzheimer's and other Dementias), which is designed to help persons in the preclinical or early stage of ADRD engage in conversations about, document, and share their end-of-life values and preferences with a care partner, extended family members, and health care providers.

Condition or Disease Intervention/Treatment Phase
  • Other: LEADing Dementia End-of-Life Planning Conversations
N/A

Detailed Description

Advance care planning is the process that allows individuals to express their future healthcare values and preferences so that these wishes can be enacted in the event that they become incapacitated and unable to participate in their own healthcare decisions. In the case of Alzheimer's disease or related dementia (ADRD), the person with dementia (care recipient), almost inevitably loses decisional capacity toward the end of life, given the progressive decline in cognitive functioning that accompanies the disease over time. The care partners to persons with dementia, most often family members such as spouse/partners and adult children, are therefore tasked with making end-of-life decisions on behalf of the care recipient with ADRD. These care partners are not always well-informed of the care recipient's end-of-life values and preferences and therefore may not feel confident in their ability to make decisions regarding care and treatment at the end-of-life, resulting in unnecessary, futile, and often unwanted medical treatments and interventions. Oftentimes, families do not want to engage in these challenging conversations and wait too long, whereby the care recipient with ADRD no longer has the decisional ability to participate in the advance care planning process. We developed "The LEAD Guide" (Life-Planning in Early Alzheimer's and other Dementias), as a tool to help persons with preclinical awareness of ADRD risk and those with early-stage cognitive impairment to begin these important conversations with a care partner. In this NIH Stage-1 behavioral intervention study we will refine the LEAD Intervention based on our pilot work (Stage 1A) and then evaluate the usability, acceptability, feasibility, and initial efficacy of the LEAD Intervention (Stage 1B). We will recruit a diverse sample of 60 community-dwelling ADRD pairs, defined as a care recipient in the preclinical or early stage of ADRD, plus their current or anticipated care partner (i.e., spouse/partner or adult child). Results are expected to show that the LEAD Intervention can improve outcomes related to decision-making self-efficacy through greater advance care planning congruence and improve subjective well-being, anxiety, and relationship quality as perceived and reported by both the care recipient and the care partner. Results from this study have the potential to guide and accelerate the implementation of the LEAD Intervention in community and healthcare practice, where a dementia-focused advance care process is needed.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
The LEAD Intervention is a web-baed platform that integrates the LEAD Guide with self-paced educational modules that guide care recipient-care partner pairs through conversations and the process of dementia-focused advance care planning. The aims of this study are: 1. To describe the acceptability, usability, and feasibility of the LEAD Intervention. Methods: Conduct a process evaluation using survey-based outcome assessments and qualitative analysis of participant-recorded advance care planning conversation(s)to identify facilitators and/or barriers to intervention participation. 2. To assess the initial efficacy of the LEAD Intervention on the primary outcome and secondary outcomes as perceived by both the care recipient and the care partner. 3. To examine advance care planning congruence as a mechanism of action for the LEAD Intervention.The LEAD Intervention is a web-baed platform that integrates the LEAD Guide with self-paced educational modules that guide care recipient-care partner pairs through conversations and the process of dementia-focused advance care planning. The aims of this study are: 1. To describe the acceptability, usability, and feasibility of the LEAD Intervention. Methods: Conduct a process evaluation using survey-based outcome assessments and qualitative analysis of participant-recorded advance care planning conversation(s)to identify facilitators and/or barriers to intervention participation. 2. To assess the initial efficacy of the LEAD Intervention on the primary outcome and secondary outcomes as perceived by both the care recipient and the care partner. 3. To examine advance care planning congruence as a mechanism of action for the LEAD Intervention.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
LEADing Dementia End-of-Life Planning Conversations
Anticipated Study Start Date :
Feb 1, 2024
Anticipated Primary Completion Date :
Jun 30, 2027
Anticipated Study Completion Date :
Jun 30, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: ADRD dyads

This is a single-arm study enrolling 60 ADRD community-based dyads.

Other: LEADing Dementia End-of-Life Planning Conversations
The LEAD Intervention is self-administered and delivered through an interactive, web-based platform designed according to recommended functionalities and user-designed principles. Through three distinct modules, the LEAD Intervention will facilitate the advance care planning processes of 1) defining care recipients' values and preferences for care, 2) developing advance care planning congruence within the pair, or a shared understanding of the care recipient's values and preferences, through conversation(s), and 3) encouraging ongoing advance care planning conversation and documentation that can be shared beyond the pair. All modules will include video tutorials to introduce the goals and tasks as well as provide interactive resources to provide support and education relevant to the content of each module. The three modules are intended to be followed in a sequential pattern.

Outcome Measures

Primary Outcome Measures

  1. Decision-Making Self-Efficacy [Week 20]

    Decision-making efficacy as measured by both the care recipient and care partner as measured by the Family Decision-Making Self-Efficacy Scale

Secondary Outcome Measures

  1. Relationship Quality [Week 20]

    Relationship quality as measured by both the care recipient and care partner as measured by the Dyadic Relationship Scale (DRS)

  2. Anxiety [Week 20]

    Perceived symptoms of anxiety by both the care recipient and care partner as measured by the PROMIS Emotional Distress-Anxiety-Short Form 8a

  3. Subjective well-being [Week 20]

    Perceived subjective well being of care recipient and care partner as measured by the PROMIS General Life Satisfaction- Short Form 5a

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

ADRD Pairs = 1 care recipient + 1 care partner, where: 1) The care recipient self-reports having subjective cognitive complaints indicative of the preclinical or early stage of ADRD and 2) The care partner self-identifies as a spouse, long-term partner, or adult child of the care recipient.

Preclinical is defined as having self-reported subjective cognitive complaints, measured using the Alzheimer's Association's "10 Warning Signs" checklist (participants must self-report having at least one warning sign), or self-report of having received a diagnosis of "mild cognitive impairment" (MCI) from a health care provider.

Early Stage is defined by the criteria outlined by the Alzheimer's Association. In the early stage, a person may be able to function independently but is aware that he or she is having memory lapses, such as forgetting words or locations of everyday objects. Persons close to the individual with memory loss may notice changes, such as trouble coming up with the right word or name, trouble remembering names when introduced to new people, difficulty performing social or work tasks, forgetting information that he or she just read, misplacing objects, and trouble with planning or organizing.

Exclusion Criteria:

Previous engagement in advance care planning (defined as the completion of a medical advance directive for the care recipient).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Utah
  • National Institute on Aging (NIA)

Investigators

  • Principal Investigator: Kara Dassel, PhD, University of Utah

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Kara Dassel, Professor, Assistant Dean, University of Utah
ClinicalTrials.gov Identifier:
NCT05909189
Other Study ID Numbers:
  • GRANT13319762
  • 1R01AG069033-01A1
First Posted:
Jun 18, 2023
Last Update Posted:
Jun 18, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kara Dassel, Professor, Assistant Dean, University of Utah
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 18, 2023